Today: 29 June 2026
Browse Category

Healthcare Innovation 8 October 2025 - 28 October 2025

From Cannabis Clinics to Bitcoin Billions: KindlyMD (NAKA) Stock’s Wild 2025 Ride

From Cannabis Clinics to Bitcoin Billions: KindlyMD (NAKA) Stock’s Wild 2025 Ride

KindlyMD (NASDAQ: NAKA) shares soared 650% to $29 after merging with Bitcoin holding firm Nakamoto Holdings in August 2025, then crashed 96% to $0.65 amid dilution fears. The company raised $710 million to buy 5,744 BTC and filed for up to $5 billion in new stock sales. Recent loans and partnerships aim to refinance debt. Analysts remain split as NAKA trades near $1, with weak earnings and high volatility.
28 October 2025
····
Pharma Giants Converge in Frankfurt – Obesity Drug Boom & Tech Innovations Fuel $1.7 Trillion Industry Future

Pharma Giants Converge in Frankfurt – Obesity Drug Boom & Tech Innovations Fuel $1.7 Trillion Industry Future

Over 62,000 pharmaceutical professionals from more than 170 countries are attending CPHI Frankfurt 2025, where executives are meeting to address global supply chain, regulation, and innovation challenges. Eli Lilly’s GLP-1 drugs generated $6.1 billion in Q1 2025, overtaking Novo Nordisk in the U.S. weight-loss drug market. Pharma giants are investing heavily as the global obesity treatment market is projected to reach $100 billion by 2030.
28 October 2025
····
CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

CRISPR Therapeutics shares traded near $69 in mid-October after rising about 40–45% over the past year. The company plans to raise up to $600 million in a new share offering announced October 15. Bank of America raised its price target to $93 and maintained a Buy rating. CRISPR reported preclinical success for CTX460 and continues to expand Casgevy’s commercial reach.
19 October 2025
···
GRAIL (GRAL) Stock Skyrockets on Samsung’s $110M Bet and Cancer-Screening Breakthrough

GRAIL (GRAL) Stock Skyrockets on Samsung’s $110M Bet and Cancer-Screening Breakthrough

GRAIL shares surged 13–14% to a record $85.35 on Oct. 16 after announcing a $110 million equity deal with Samsung and plans to bring its Galleri cancer test to Asia. New trial data at ESMO showed Galleri doubled early cancer detection versus routine screening. Despite gains, most analysts rate GRAL a “Hold” with an average target below current prices. Q2 revenue rose 11% to $35.5M; net loss narrowed to $114M.
18 October 2025
···
Femasys (FEMY) Stock Soars 46% on Fertility Tech and FDA Milestones

Femasys (FEMY) Stock Soars 46% on Fertility Tech and FDA Milestones

Femasys (NASDAQ: FEMY) jumped 46% to $0.80 by mid-day Oct. 16 after announcing its FemaSeed fertility treatment will be showcased at ASRM 2025. The company recently secured European, UK, and New Zealand approvals for its FemBloc birth control device and reported its first European sales and new distribution deals. Q2 revenue rose 85% year-over-year to $0.409 million.
16 October 2025
··
Turn Therapeutics (TTRX) Skyrockets After Nasdaq Debut – Biotech Breakthrough or Hype?

Turn Therapeutics (TTRX) Skyrockets After Nasdaq Debut – Biotech Breakthrough or Hype?

Turn Therapeutics shares surged to around $23 midday Oct. 9 after opening at $24.50, following a prior close of $7. Market cap jumped to over $500 million from under $100 million. The stock debuted on Nasdaq Oct. 8 via direct listing and has traded with extreme volatility, more than tripling in value amid speculative interest. No new FDA approvals were announced this week.
9 October 2025
··
Tempus AI (TEM) Stock Skyrockets on AI Healthcare Breakthroughs – What Investors Need to Know

Tempus AI (TEM) Stock Skyrockets on AI Healthcare Breakthroughs – What Investors Need to Know

Tempus AI shares closed at a record $102.31 on October 8, 2025, nearly tripling year-to-date after FDA clearance for new AI diagnostics and the $81.3 million acquisition of Paige. Q2 revenue surged 89.6% to $314.6 million, with net losses narrowing and positive adjusted EBITDA forecast for 2025. Market cap stands near $17 billion.
8 October 2025
···
1 2

Stock Market Today

  • Top 10 Most Shorted ASX Stocks and Weekly Market Movers
    June 28, 2026, 11:00 PM EDT. The latest Short Seller Series highlights the 10 most heavily shorted stocks on the Australian Securities Exchange (ASX). This report also tracks significant weekly shifts in short interest, indicating which stocks are attracting more or less bearish bets. Investors often study short interest as it reflects market sentiment, showing which shares traders expect to fall. This update provides insight into the biggest risers and fallers in short positions, helping investors gauge potential market moves and emerging risks.

Latest articles

Trump-era loan caps could open door for private lenders in grad school market

Trump-era loan caps could open door for private lenders in grad school market

29 June 2026
July 1 federal loan caps slash Grad PLUS access, forcing many graduate and professional students to seek private loans; Sallie Mae projects up to 70% origination growth over several years, while SoFi reports record student-loan volume—investors now face a real-time test of how much demand shifts to private lenders as federal limits hit.
IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

29 June 2026
IREN Limited (NASDAQ:IREN) plunged 21.3% to $47.21 over five straight down days despite announcing a record $50M+ annual Warriors jersey deal, as investors focused on the company’s not fully contracted $4.4B target ARR and high short interest at 19.74% of float, with Friday’s close near the lowest analyst target.
Go toTop